・The Haelo Phase 3 trial marks the first late-stage test of an in-vivo CRISPR gene-editing treatment. ・Earlier mid-stage studies showed a 96% reduction in monthly attack rates, with 97% of patients ...

Shares of Intellia Therapeutics, Inc. (NTLA) have gained 14.9% over the past four weeks to close the last trading session at $7.88, but there could still be a solid upside left in the stock if ...

Intellia Therapeutics, Inc. (NTLA) shares rallied 6.5% in the last trading session to close at $12.28. This move can be attributable to notable volume with a higher number of shares being traded than ...

Intellia's peak HAE market share is estimated at just 4%, reflecting patient hesitancy for one-time gene edits. Learn why ...

Shares of Intellia Therapeutics NTLA have rallied sharply over the past month, supported by positive regulatory and clinical milestones for one of its lead candidates, lonvoguran ziclumeran (lonvo-z; ...

Eliana Clark, the EVP of $NTLA, sold 1,022 shares of the company on 07-01-2025 for an estimated $10,036. We received data on the trade from a recent SEC filing. This ...

Why Intellia Therapeutics Stock Is Back in Focus Intellia Therapeutics (NTLA) is back on investors’ radar after announcing successful Phase 3 trial results for its gene editing treatment Lonvo-z and ...

On Thursday, Intellia Therapeutics, Inc. (NASDAQ:NTLA) released Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary angioedema (HAE). NTLA-2002 is an investigational ...

Intellia Therapeutics has staged a sharp rebound in 2026, yet its long term track record and current valuation checks suggest the stock may still be priced with little room for disappointment. The ...